Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover Trial - PubMed
3 hours ago
- #IgA nephropathy
- #proteinuria
- #clinical trial
- Atrasentan significantly reduces proteinuria in IgA nephropathy patients already on RAS and SGLT2 inhibitors.
- The randomized crossover trial showed a -25.3% difference in UPCR at week 12 and -26.4% at week 24 compared to placebo.
- Atrasentan was well-tolerated with minimal fluid retention events, no related serious adverse events, and no treatment discontinuations.